KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2025)

Recursion Pharmaceuticals' Free Cash Flow history spans 6 years, with the latest figure at -$47.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 54.27% year-over-year to -$47.3 million; the TTM value through Dec 2025 reached -$378.3 million, down 5.19%, while the annual FY2025 figure was -$378.3 million, 5.19% down from the prior year.
  • Free Cash Flow reached -$47.3 million in Q4 2025 per RXRX's latest filing, up from -$122.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $73.1 million in Q1 2022 to a low of -$133.1 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$66.2 million, with a median of -$72.6 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 2560.27% in 2021, then surged 332.23% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$68.5 million in 2021, then dropped by 14.92% to -$78.7 million in 2022, then grew by 3.26% to -$76.1 million in 2023, then plummeted by 35.89% to -$103.5 million in 2024, then skyrocketed by 54.27% to -$47.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Free Cash Flow are -$47.3 million (Q4 2025), -$122.3 million (Q3 2025), and -$75.5 million (Q2 2025).